These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor. Eliaz R; Wallach D; Kost J Cytokine; 1996 Jun; 8(6):482-7. PubMed ID: 8818545 [TBL] [Abstract][Full Text] [Related]
3. In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence. Nieto K; Pei P; Wang D; Mallery SR; Schwendeman SP Int J Pharm; 2018 Mar; 538(1-2):48-56. PubMed ID: 29170116 [TBL] [Abstract][Full Text] [Related]
4. Antiarthritic activity of soluble tumor necrosis factor receptor type I forms in adjuvant arthritis: correlation of plasma levels with efficacy. McComb J; Gould T; Chlipala E; Sennelo G; Frazier J; Kieft G; Seely J; Edwards CK; Bendele A J Rheumatol; 1999 Jun; 26(6):1347-51. PubMed ID: 10381054 [TBL] [Abstract][Full Text] [Related]
5. Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets. Leelakanok N; Geary SM; Salem AK J Pharm Sci; 2018 Feb; 107(2):690-697. PubMed ID: 29031952 [TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres. Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541 [TBL] [Abstract][Full Text] [Related]
7. Pharmacologic response of a controlled-release PLGA formulation for the alpha-melanocyte stimulating hormone analog, Melanotan-I. Bhardwaj R; Hadley ME; Dorr RT; Dvorakova K; Brooks C; Blanchard J Pharm Res; 2000 May; 17(5):593-9. PubMed ID: 10888312 [TBL] [Abstract][Full Text] [Related]
8. Design and development of a novel controlled release PLGA alginate-pectinate polyspheric drug delivery system. Sweet JL; Pillay V; Choonara YE Drug Deliv; 2007 Jul; 14(5):309-18. PubMed ID: 17613019 [TBL] [Abstract][Full Text] [Related]
9. Physicochemical characterization of photopolymerizable PLGA blends. Baroli B Adv Exp Med Biol; 2006; 585():183-96. PubMed ID: 17120785 [No Abstract] [Full Text] [Related]
10. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres. Sinha VR; Trehan A Drug Deliv; 2005; 12(3):133-9. PubMed ID: 16025842 [TBL] [Abstract][Full Text] [Related]
11. Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer. Gangadharam PR; Ashtekar DR; Farhi DC; Wise DL Tubercle; 1991 Jun; 72(2):115-22. PubMed ID: 1949214 [TBL] [Abstract][Full Text] [Related]
12. Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. Gangadharam PR; Kailasam S; Srinivasan S; Wise DL J Antimicrob Chemother; 1994 Feb; 33(2):265-71. PubMed ID: 8182007 [TBL] [Abstract][Full Text] [Related]
14. A novel polyethylene depot device for the study of PLGA and P(FASA) microspheres in vitro and in vivo. Sandor M; Harris J; Mathiowitz E Biomaterials; 2002 Nov; 23(22):4413-23. PubMed ID: 12219832 [TBL] [Abstract][Full Text] [Related]
15. In-vivo release of a GnRH agonist from a slow-release poly(lactide-glycolide) copolymer preparation: comparison in rat, rabbit and guinea-pig. Heinrich N; Fechner K; Berger H; Lorenz D; Albrecht E; Rafler G; Schäfer H; Mehlis B J Pharm Pharmacol; 1991 Nov; 43(11):762-5. PubMed ID: 1686903 [TBL] [Abstract][Full Text] [Related]
16. An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. Deadman CM; Kellaway IW; Yasin M; Dickinson PA; Murdan S J Control Release; 2007 Sep; 122(1):79-85. PubMed ID: 17638603 [TBL] [Abstract][Full Text] [Related]
17. Protein instability in poly(lactic-co-glycolic acid) microparticles. van de Weert M; Hennink WE; Jiskoot W Pharm Res; 2000 Oct; 17(10):1159-67. PubMed ID: 11145219 [TBL] [Abstract][Full Text] [Related]